Back to Results

RIVOBA

Title The Impact of a Novel Host-Protein Assay on Antibiotic Use in Acute Respiratory Illness
Therapeutic Area Respiratory Infections
Principal Investigator Justin Popso, DO
Max Age 0 Years
Gender All
Contact Justin Popso
617-636-5566
jpopso@tuftsmedicalcenter.org

Overview

We intend to use the measurement of three host-related, serum-based, protein biomarkers using a previously validated score to determine whether a patient with a suspected respiratory illness has a bacterial or viral immune response (or equivocal).  These results will then be compared to the decision of the clinical provider to prescribe antibiotics as documented in the patient chart and allow for calculation of potential antibiotic use reduction.

Study Details

Inclusion Criteria

  • Symptoms <= 7 days and
  • Experienced fever (> 38 o C or self-reported) or
  • Clinical suspicion of infectious respiratory illness

Exclusion Criteria

  • Confirmed and/or suspected acute gastroenteritis
  • Congenital or acquired immune deficiency
  • Chronic fungal or parasitic infection
  • Infection with human immunodeficiency (HIV), Hepatitis B virus (HBV), Hepatitis C virus (HCV)
  • ·-nfection with active tuberculosis (TB)
  • Significant trauma or burns in the last 7 days
  • Patients that have undergone major surgery in the last 7 days
  • Pregnant women
  • Active malignancy
  • Confirmed COVID-19

Study Requirements

One visit, one blood sample of 1 ml but no more that 5 ml of serum